Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Danish pharmaceutical firm Novo Nordisk has opened a new manufacturing facility in Russia for formulation and filling of modern insulin to treat diabetes.
Subscribe to our email newsletter
At the new facility, the company will produce both Penfill cartridges and FlexPen prefilled insulin injection pens for the Russian market.
Located in Technopark Grabtsevo in the Kaluga region of Russia, the new facility will be operating in accordance with current Good Manufacturing Practices (GMP).
Novo Nordisk CEO Lars Rebien Sørensen said: "The manufacturing facility in Kaluga is a sign of our long-term commitment to people with diabetes in Russia, where close to 10 million people have the disease according to local studies.
"With our investment in local manufacturing, we ensure availability of high-quality modern insulins to the people with diabetes in Russia who rely on our products every day."
The new plant is claimed to be the first and only greenfield facility for the manufacturing of modern insulin in the country.
Kaluga Region Governor Anatoly Artamonov said: "The opening of Novo Nordisk manufacturing facility in Kaluga is a sign of confidence in our region, as well as an important stage in the formation of a pharmaceutical cluster in Kaluga.
"I am convinced that the new facility will have a significant impact on improving the quality of life for people with diabetes in Kaluga as well as in the rest of Russia."
The Danish firm also has production facilities in Brazil, China, France and the US.
Image: Novo Nordisk’s new Russian plant will produce both Penfill cartridges and FlexPen prefilled insulin injection pens. Photo: courtesy of Baitong333/ freedigitalphotos.net.